Zilbesarian, an RNA Interference Agent, Shows Promise for Hy

A multipart, phase 1 trial provides evidence demonstrating the safety of zilbesarian, an RNA interference agent, which appeared to have a favorable safety profile among adult patients with hypertension.

Related Keywords

United Kingdom , United States , American , Simon Fox , Akshay Desai , Heart Failure Program , Alnylam Pharmaceuticals Inc , Investor Relations Alnylam Pharmaceuticals Inc , American Heart Association , Alnylam Pharmaceuticals , A Report From The American Heart Association , New England Journal , Advanced Heart Disease Section , Cardiovascular Division , England Journal , Investor Relations , Report From , Hypertension , Zilbesarian , Rna Intereference , Rna Agent , Roche , Alnylam And Roche ,